5min chapter

Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

Pelobressev's Confidence Interval Is Higher Than the Other Drug

Pelobressev has improved efficacy and no increased toxicity. The lower, to me, the lower bound of the confidence interval on it is actually higher than that for other drug. We're going to increase our enrollment from 300 to 400 patients to make sure that we have the highest degree of success in that symptom score reduction. And again, you can tell me if I'm putting words in your team, we're more positive.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode